Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02393157
Title Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York Medical College
Indications

B-cell lymphoma

Burkitt lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

primary mediastinal B-cell lymphoma

lymphoblastic lymphoma

Therapies

Carboplatin + Etoposide + Ifosfamide + Obinutuzumab

Cytarabine

Age Groups: adult | child
Covered Countries USA


No variant requirements are available.